Why aren't there better treatments for cramps?; Pfizer scraps half of participants in Lyme disease vaccine trial

An estimated 1 in 5 people with period pain don't get relief from existing treatments. But research into better options has faltered.

February 17, 2023 Check out STAT+

Sponsored By

Molly Ferguson for STAT Current treatments for cramps aren't cutting it. Why aren't there better options? An estimated 1 in 5 people with period pain don't get relief from existing treatments. But research into better options has faltered. By Calli McMurray STAT+ | Christi Shaw, leader of Gilead's cancer cell therapy unit, to depart Christi Shaw, who took the CEO role in July 2019, was inspired to join Kite in part by the experience of watching her sister fight cancer. By Matthew Herper and Adam Feuerstein STAT+ | Pfizer scraps half of participants in Lyme disease drug trial due to quality issues Pfizer and partner Valneva's trial for a Lyme disease vaccine candidate hit a snag due to quality issues with a third-party trial operator. By Allison DeAngelis Miliken Institute STAT+ | Ginkgo chief Jason Kelly is chairing a federal biotech advisory group. Is that a conflict of interest? Jason Kelly will chair the commission while heading Ginkgo, with a roughly 6% stake in the company currently valued at over $100 million. By Jason Mast STAT+ | Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more PhRMA's new chair talks with STAT about the industry's struggles in Washington, the future of Novartis, and whether the biotech sector is still overvalued. By Meg Tirrell and Adam Feuerstein and Damian Garde STAT+ | Reata's 'toss up' drug approval decision is in the unpredictable hands of FDA's Billy Dunn Will Billy Dunn apply the doctrine of "regulatory flexibility" to a medicine from Reata with less-than-convincing clinical data? By Adam Feuerstein Adobe Opinion: Another pharma industry flip-flop: Claims about the IRA's effect on small-molecule versus biologic drugs Claims that the Inflation Reduction Act will disadvantage small-molecule drugs vs. biologics are misleading and not supported by the facts. By David Mitchell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser